ArticleScientific reports2021

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment.

A Farias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.